Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
K
0082N0
vs
K
KOSPI 200
Over the past 12 months, 0082N0 has underperformed KOSPI 200, delivering a return of -12% compared to KOSPI 200's +108% growth.
Stocks Performance
0082N0 vs KOSPI 200
Performance Gap
0082N0 vs KOSPI 200
Performance By Year
0082N0 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Kanaph Therapeutics Inc
Glance View
Kanaph Therapeutics Inc. engages in the research and development of antibody drugs based on human genome based drug development technology. The company is headquartered in Seoul, Seoul. The company went IPO on 2026-03-16. The firm is engaged in the research and development of anticancer drugs and ophthalmic disease treatments based on human genome-based drug discovery technologies. The firm primarily researches and develops bispecific antibodies including immuno-oncology and ophthalmic disease treatments, targeted anticancer antibody-drug conjugate (ADC) new drugs and ADC platform technologies. The firm also provides synthetic new drugs including immuno-oncology drugs and targeted anticancer drugs.